PriceTargets.com logo

NASDAQ:IRTC - iRhythm Technologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $156.67
  • Forecasted Upside: 20.45 %
  • Number of Analysts: 10
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$130.07 As of 01/20/2022 01:00 AM ET
▲ +2.4 (1.88%)

This chart shows the closing price for IRTC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New iRhythm Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IRTC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IRTC

Analyst Price Target is $156.67
▲ +20.45% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for iRhythm Technologies in the last 3 months. The average price target is $156.67, with a high forecast of $185.00 and a low forecast of $116.00. The average price target represents a 20.45% upside from the last price of $130.07.

This chart shows the closing price for IRTC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 10 polled investment analysts is to buy stock in iRhythm Technologies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/21/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/18/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$129.00 ➝ $167.00High
1/14/2022Canaccord Genuity GroupBoost Price TargetBuy ➝ Buy$125.00 ➝ $160.00Low
1/14/2022Canaccord Genuity GroupBoost Price TargetBuy ➝ Buy$125.00 ➝ $160.00Low
1/14/2022CitigroupBoost Price TargetBuy$120.00 ➝ $165.00Low
1/13/2022Truist FinancialBoost Price Target$130.00 ➝ $185.00Low
1/12/2022Robert W. BairdBoost Price Target$110.00 ➝ $137.00Low
1/12/2022BTIG ResearchUpgradeNeutral ➝ Buy$170.00Low
1/11/2022OppenheimerUpgradeMarket Perform ➝ Outperform$150.00High
1/7/2022Morgan StanleyBoost Price TargetEqual Weight$114.00 ➝ $129.00Medium
12/17/2021JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$100.00 ➝ $116.00High
12/15/2021CitigroupUpgradeNeutral ➝ Buy$120.00High
11/8/2021Morgan StanleyBoost Price TargetEqual Weight$77.00 ➝ $114.00Low
11/5/2021CitigroupBoost Price TargetNeutral$60.00 ➝ $120.00Medium
10/14/2021JPMorgan Chase & Co.Boost Price TargetNeutral$55.00 ➝ $70.00Low
10/1/2021CitigroupBoost Price TargetNeutral$55.00 ➝ $60.00Low
8/6/2021CitigroupLower Price TargetNeutral$74.00 ➝ $55.00High
6/3/2021Morgan StanleyLower Price TargetEqual Weight$94.00 ➝ $85.00Low
6/2/2021Needham & Company LLCReiterated RatingHoldHigh
6/2/2021CitigroupDowngradeBuy ➝ NeutralHigh
4/20/2021Morgan StanleyReiterated RatingOverweight ➝ Equal Weight$288.00 ➝ $94.00High
4/19/2021BTIG ResearchReiterated RatingBuy ➝ NeutralN/A
4/14/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$288.00 ➝ $94.00High
4/13/2021Truist FinancialLower Price Target$220.00 ➝ $115.00Low
4/13/2021BTIG ResearchDowngradeBuy ➝ NeutralHigh
4/12/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$215.00 ➝ $95.00High
4/12/2021Robert W. BairdLower Price TargetNeutral$170.00 ➝ $80.00High
3/4/2021Colliers SecuritiesReiterated RatingBuy ➝ NeutralN/A
3/1/2021CitigroupLower Price TargetBuy$252.00 ➝ $195.00Low
2/28/2021Robert W. BairdReiterated RatingHoldLow
2/26/2021Colliers SecuritiesDowngradeBuy ➝ NeutralHigh
2/4/2021BTIG ResearchLower Price TargetBuy$283.00 ➝ $210.00Low
2/1/2021Truist FinancialLower Price Target$265.00 ➝ $220.00Low
1/29/2021Needham & Company LLCReiterated RatingHoldHigh
1/25/2021Morgan StanleyBoost Price TargetOverweight$227.00 ➝ $288.00High
1/21/2021BTIG ResearchBoost Price TargetBuy$235.00 ➝ $283.00High
12/15/2020Morgan StanleyLower Price TargetOverweight$230.00 ➝ $227.00High
12/10/2020William BlairReiterated RatingBuyMedium
12/3/2020Truist FinancialLower Price Target$265.00 ➝ $240.00Medium
12/3/2020Smith Barney CitigroupLower Price Target$275.00 ➝ $238.00Medium
12/3/2020Robert W. BairdLower Price TargetNeutral$220.00 ➝ $170.00High
12/2/2020Morgan StanleyLower Price TargetOverweight$270.00 ➝ $230.00High
11/17/2020OppenheimerDowngradeOutperform ➝ Market PerformHigh
11/17/2020Needham & Company LLCReiterated RatingHoldHigh
11/6/2020Truist FinancialBoost Price Target$200.00 ➝ $265.00Low
11/6/2020Morgan StanleyBoost Price TargetOverweight$259.00 ➝ $270.00Low
11/6/2020OppenheimerReiterated RatingBuy$200.00 ➝ $250.00High
10/12/2020BTIG ResearchBoost Price Target$130.00 ➝ $160.00Low
9/11/2020Needham & Company LLCInitiated CoverageHoldLow
9/1/2020Robert W. BairdInitiated CoverageNeutral$220.00Medium
8/25/2020CitigroupBoost Price TargetBuy$215.00 ➝ $250.00Low
8/7/2020Colliers SecuritiesUpgradeNeutral ➝ Buy$200.00High
8/5/2020CitigroupBoost Price TargetBuy$147.00 ➝ $200.00High
8/5/2020OppenheimerUpgradeMarket Perform ➝ Outperform$200.00High
5/8/2020JPMorgan Chase & Co.Boost Price TargetOverweight$125.00 ➝ $140.00Low
5/8/2020Morgan StanleyBoost Price TargetOverweight$114.00 ➝ $142.00Low
5/8/2020SunTrust BanksBoost Price TargetBuy$102.00 ➝ $130.00High
5/8/2020BTIG ResearchReiterated RatingBuy$130.00High
5/8/2020OppenheimerReiterated RatingHoldHigh
3/27/2020Morgan StanleyBoost Price TargetOverweight$110.00 ➝ $114.00High
3/27/2020CitigroupLower Price TargetBuy$120.00 ➝ $112.00High
3/4/2020CitigroupInitiated CoverageBuy$120.00Medium
2/5/2020BTIG ResearchInitiated CoverageBuy$90.00Low
1/9/2020William BlairInitiated CoverageOutperformHigh
1/7/2020SunTrust BanksInitiated CoverageBuy$102.00High
12/17/2019Morgan StanleyBoost Price TargetOverweight$101.00 ➝ $110.00Low
10/22/2019OppenheimerInitiated CoverageMarket PerformLow
8/1/2019JPMorgan Chase & Co.Boost Price TargetOverweight$110.00 ➝ $125.00High
7/31/2019BTIG ResearchSet Price TargetBuy$90.00N/A
5/8/2019BTIG ResearchBoost Price TargetPositive ➝ Buy$90.00High
4/3/2019BTIG ResearchUpgradeNeutral ➝ Buy$80.00Medium
2/20/2019Chardan CapitalDowngradeBuy ➝ Neutral$111.00 ➝ $104.00Low
2/13/2019Royal Bank of CanadaBoost Price TargetOutperform$109.00Low
2/13/2019JPMorgan Chase & Co.Boost Price Target$110.00Low
2/13/2019Morgan StanleyBoost Price TargetOverweight ➝ Overweight$85.00 ➝ $101.00Medium
2/13/2019Northland SecuritiesReiterated RatingHold$75.00High
2/13/2019BTIG ResearchReiterated RatingHoldMedium
2/13/2019BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$96.00 ➝ $105.00High
10/11/2018Morgan StanleyBoost Price TargetOverweight$92.00 ➝ $95.00High
9/6/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$117.00Medium
8/2/2018Dougherty & CoUpgradeSell ➝ NeutralHigh
8/2/2018BTIG ResearchReiterated RatingHoldHigh
8/2/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$86.00 ➝ $92.00High
8/2/2018JPMorgan Chase & Co.Reiterated RatingOverweight$100.00High
8/2/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$93.00 ➝ $96.00High
7/16/2018Dougherty & CoDowngradeNeutral ➝ SellMedium
7/10/2018BMO Capital MarketsBoost Price TargetOutperform$93.00High
6/13/2018Royal Bank of CanadaBoost Price TargetOutperform$91.00Medium
6/4/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$70.00 ➝ $86.00Low
4/16/2018Northland SecuritiesReiterated RatingHold$60.00Low
3/14/2018Northland SecuritiesReiterated RatingHold$60.00Low
3/5/2018BMO Capital MarketsInitiated CoverageOutperform$76.00Medium
2/15/2018JPMorgan Chase & Co.Boost Price TargetOverweight ➝ Overweight$62.00 ➝ $67.00High
12/4/2017Royal Bank of CanadaInitiated CoverageOutperform$79.00High
12/1/2017Dougherty & CoInitiated CoverageNeutral ➝ NeutralMedium
11/3/2017Morgan StanleyBoost Price TargetOverweight$50.00 ➝ $65.00N/A
6/6/2017Morgan StanleyBoost Price TargetOverweight$43.00 ➝ $47.00High
(Data available from 1/20/2017 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2021
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2021
  • 3 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2021
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2021
  • 5 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2021
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2021
  • 7 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
1/20/2022

Current Sentiment

  • 7 very positive mentions
  • 24 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

iRhythm Technologies logo
iRhythm Technologies, Inc. engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, continuously records, and stores ECG data from every patient heartbeat for up to 14 consecutive days; and Zio AT, also provides ECG data but also provides physicians with actionable notifications during the wear period. The company was founded by Uday N. Kumar in September 2006 and is headquartered in San Francisco, CA.
Read More

Today's Range

Now: $130.07
Low: $128.97
High: $134.24

50 Day Range

MA: $110.49
Low: $89.18
High: $143.12

52 Week Range

Now: $130.07
Low: $41.66
High: $286.19

Volume

386,049 shs

Average Volume

628,563 shs

Market Capitalization

$3.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21

Frequently Asked Questions

What sell-side analysts currently cover shares of iRhythm Technologies?

The following Wall Street sell-side analysts have issued research reports on iRhythm Technologies in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Colliers Securities, JPMorgan Chase & Co., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Robert W. Baird, TheStreet, Truist Financial Co., and Zacks Investment Research.
View the latest analyst ratings for IRTC.

What is the current price target for iRhythm Technologies?

9 Wall Street analysts have set twelve-month price targets for iRhythm Technologies in the last year. Their average twelve-month price target is $156.67, suggesting a possible upside of 20.4%. Truist Financial Co. has the highest price target set, predicting IRTC will reach $185.00 in the next twelve months. JPMorgan Chase & Co. has the lowest price target set, forecasting a price of $116.00 for iRhythm Technologies in the next year.
View the latest price targets for IRTC.

What is the current consensus analyst rating for iRhythm Technologies?

iRhythm Technologies currently has 3 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IRTC will outperform the market and that investors should add to their positions of iRhythm Technologies.
View the latest ratings for IRTC.

What other companies compete with iRhythm Technologies?

Other companies that are similar to iRhythm Technologies include Teleflex, Abiomed, Penumbra, Tandem Diabetes Care, NovoCure, Globus Medical, Inspire Medical Systems, Integra LifeSciences, ShockWave Medical, ICU Medical, Inari Medical, Merit Medical Systems, Nevro, NuVasive and AtriCure.

How do I contact iRhythm Technologies' investor relations team?

iRhythm Technologies' physical mailing address is 650 TOWNSEND STREET SUITE 500, San Francisco CA, 94103. The company's listed phone number is (415) 632-5700 and its investor relations email address is [email protected] The official website for iRhythm Technologies is www.irhythmtech.com.